Tag: Bioxyne
Bioxyne signs $5.6M supply agreement to enter German medical cannabis market
Bioxyne Limited), through its subsidiary Breathe Life Sciences (BLS), has entered the German medical cannabis market by securing a commercial supply agreement worth a minimum of €3.2 million (approximately AUD 5.6 million) for FY2026.
Bioxyne granted Australia’s first GMP licence for Psilocybin and MDMA manufacturing
Bioxyne Limited's subsidiary, Breathe Life Sciences (BLS), has secured the Good Manufacturing Practice (GMP) licence for the production of medical cannabis.
Featured Article
The economic forces driving manufacturing’s next cycle
Australia’s manufacturing sector entered 2026 with improving momentum, but renewed global disruption is again testing resilience across the industry.
